Andrea Brancale, Kara Carter, Leen Delang, Jerome Deval, David Durantel, Brian G Gentry, Robert Jordan, Justin G. Julander, Michael K. Lo, Maria-Jesús Pérez-Pérez, Luis M. Schang, Katherine L. Seley-Radtke, Pei-Yong Shi, Subhash G. Vasudevan, Richard J. Whitley, Jessica R. Spengler, Cardiff University, Evotec SE, Hamburg, Germany, KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium, Aligos Therapeutics, Inc., San Francisco, CA, USA, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Drake University, Des Moines, IA, USA, Bill and Melinda Gates Foundation, Seattle, WA, USA, Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA, Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA, Instituto de Química Médica (IQM-CSIC), Madrid, Spain, Baker Institute for Animal Health and Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA, Department of Chemistry & Biochemistry, University of Maryland, Baltimore, MD, USA, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA, and Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland, Australia
As a result of the multiple gathering and travels restrictions during the SARS-CoV-2 pandemic, the annual meeting of the International Society for Antiviral Research (ISAR), the International Conference on Antiviral Research (ICAR), could not be held in person in 2021. Nonetheless, ISAR successfully organized a remote conference, retaining the most critical aspects of all ICARs, a collegiate gathering of researchers in academia, industry, government and non-governmental institutions working to develop, identify, and evaluate effective antiviral therapy for the benefit of all human beings. This article highlights the 2021 remote meeting, which presented the advances and objectives of antiviral and vaccine discovery, research, and development. The meeting resulted in a dynamic and effective exchange of ideas and information, positively impacting the prompt progress towards new and effective prophylaxis and therapeutics., The author(s) received no financial support for the research, authorship, and/or publication of this article